These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 33664486)

  • 1. Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution.
    Qi H; Ma ML; Jiang HW; Ling JY; Chen LY; Zhang HN; Lai DY; Li Y; Guo ZW; Hu CS; Guo SJ; Meng QF; Ren Y; Yang X; Wang W; Zhou J; Zhao XD; Li H; Tao SC
    Cell Mol Immunol; 2021 Apr; 18(4):1067-1069. PubMed ID: 33664486
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Béguelin A
    Rev Med Suisse; 2021 Jan; 17(723):234. PubMed ID: 33507668
    [No Abstract]   [Full Text] [Related]  

  • 3. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.
    Li Y; Lai DY; Zhang HN; Jiang HW; Tian X; Ma ML; Qi H; Meng QF; Guo SJ; Wu Y; Wang W; Yang X; Shi DW; Dai JB; Ying T; Zhou J; Tao SC
    Cell Mol Immunol; 2020 Oct; 17(10):1095-1097. PubMed ID: 32895485
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.
    Zeng W; Ma H; Ding C; Yang Y; Sun Y; Huang X; He W; Xiang Y; Gao Y; Jin T
    Signal Transduct Target Ther; 2021 Jan; 6(1):35. PubMed ID: 33514692
    [No Abstract]   [Full Text] [Related]  

  • 5. SnapShot: SARS-CoV-2 antibodies.
    Montefiori DC; Acharya P
    Cell Host Microbe; 2021 Jul; 29(7):1162-1162.e1. PubMed ID: 34265246
    [No Abstract]   [Full Text] [Related]  

  • 6. IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals.
    Stanczak MA; Sanin DE; Apostolova P; Nerz G; Lampaki D; Hofmann M; Steinmann D; Krohn-Grimberghe M; Thimme R; Mittler G; Waller CF; Pearce EJ; Pearce EL
    Nat Commun; 2021 Apr; 12(1):2133. PubMed ID: 33837219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1.
    Pagano S; Yerly S; Meyer B; Juillard C; Suh N; Le Terrier C; Daguer JP; Farrera-Soler L; Barluenga S; Piumatti G; Hartley O; Lemaitre B; Eberhardt CS; Siegrist CA; Eckerle I; Stringhini S; Guessous I; Kaiser L; Pugin J; Winssinger N; Vuilleumier N
    Eur J Clin Invest; 2021 Nov; 51(11):e13661. PubMed ID: 34324704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain.
    Ip JD; Kok KH; Chan WM; Chu AW; Wu WL; Yip CC; To WK; Tsang OT; Leung WS; Chik TS; Chan KH; Hung IF; Yuen KY; To KK
    Clin Microbiol Infect; 2021 Sep; 27(9):1350.e1-1350.e5. PubMed ID: 33144203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
    Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
    Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system.
    de Queiroz NMGP; Marinho FV; Chagas MA; Leite LCC; Homan EJ; de Magalhães MTQ; Oliveira SC
    Microbes Infect; 2020; 22(10):515-524. PubMed ID: 32961274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2.
    Li C; Tian X; Jia X; Wan J; Lu L; Jiang S; Lan F; Lu Y; Wu Y; Ying T
    Signal Transduct Target Ther; 2021 Mar; 6(1):132. PubMed ID: 33758169
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Startling new variant raises urgent questions.
    Kupferschmidt K
    Science; 2021 Dec; 374(6572):1178-1180. PubMed ID: 34855503
    [No Abstract]   [Full Text] [Related]  

  • 14. Dynamic landscape mapping of humoral immunity to SARS-CoV-2 identifies non-structural protein antibodies associated with the survival of critical COVID-19 patients.
    Cheng L; Zhang X; Chen Y; Wang D; Zhang D; Yan S; Wang H; Xiao M; Liang T; Li H; Xu M; Hou X; Dai J; Wu X; Li M; Lu M; Wu D; Tian R; Zhao J; Zhang Y; Cao W; Wang J; Yan X; Zhou X; Liu Z; Xu Y; He F; Li Y; Yu X; Zhang S
    Signal Transduct Target Ther; 2021 Aug; 6(1):304. PubMed ID: 34404759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody landscape against SARS-CoV-2 reveals significant differences between non-structural/accessory and structural proteins.
    Li Y; Xu Z; Lei Q; Lai DY; Hou H; Jiang HW; Zheng YX; Wang XN; Wu J; Ma ML; Zhang B; Chen H; Yu C; Xue JB; Zhang HN; Qi H; Guo SJ; Zhang Y; Lin X; Yao Z; Sheng H; Sun Z; Wang F; Fan X; Tao SC
    Cell Rep; 2021 Jul; 36(2):109391. PubMed ID: 34242574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals.
    Yoshida S; Ono C; Hayashi H; Fukumoto S; Shiraishi S; Tomono K; Arase H; Matsuura Y; Nakagami H
    Sci Rep; 2021 Mar; 11(1):5934. PubMed ID: 33723294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France.
    Zedan HT; Nasrallah GK
    EBioMedicine; 2021 Sep; 71():103580. PubMed ID: 34525435
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
    Dalakas MC; Bitzogli K; Alexopoulos H
    Front Immunol; 2021; 12():627285. PubMed ID: 33679770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.